Is Beam Therapeutics Inc (BEAM) overvalued? · rev $63.5M
Beam Therapeutics Inc (BEAM) is a biotechnology company listed on US.
This page asks whether Beam Therapeutics Inc (BEAM) looks expensive on cached numbers — not a short thesis.
Latest reported BEAM revenue for 2024-12-31 was $63.5M. Net income was -$376.7M. Revenue was down 83.2% from 2023-12-31 to 2024-12-31. BEAM currently screens at market cap $2.01B.
BEAM currently screens at market cap $2.01B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BEAM 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BEAM stock page for the full model, not this heading.
Not investment advice.